In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates [2]

Journal of Chemotherapy

Volumn 15, Issue 3, 2003, Pages 296-298

  Kantarcioglu, A Serda ^a   Yucel, A ^a   Vidotto, V ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; N DIMETHYLAMINOACETYLPARTRICIN A2 DIMETHYLAMINOETHYLAMIDE DIASCORBATE; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; SPK 843; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; REPRODUCIBILITY;

EID: 0038345493     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.3.296     Document Type: Letter

References (15)

1. Bodey GP. Fungal infections in immunocompromised patients-Candidiasis. Infect Dis Rev 1999; 1: 4-8.
2. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
3. Sheehan DJ, Hitchock CA, Sibley M. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
4. Bruzzese T, Rimaroli C, Bonabello A, Ferrari E, Signorini M. Amide derivatives of partricin A with potent antifungal activity. Eur J Med Chem 1996; 31: 965-972.
5. Rimaroli C, Bruzzese T. In vitro antifungal activity of a new polyene, SPA-S-843, against yeast. Antimicrob Agents Chemother 1998; 42: 3012-3013.
6. nd edn. Cambridge: Cambridge University Press, 1990:111-113.
7. Warren N, Kevin CH. Candida, Cryptococcus and other yeasts of medical impotrance. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds). Manual of Clinical Microbiology. Washington DC: ASM Press, 1995: 723-737.
8. Raper K B, Fennell DI. Aspergillus. The Williams and Wilkins Company, Baltimore, Md. 1965.
9. th ed. Centraalbureau voor Schimmelcultures, Baam. 1995.
10. National Committee for Laboratory Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts. Approved Standard; Document M27-A National Committee for Laboratory Standards. Villanova, 1997.
11. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi; Proposed Standard. Document M38-P. National Committee for Clinical Laboratory Standards. Wayne, Pa. 1998: 7.
12. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and Minimum Fungicidal Concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3776-3781.
13. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-958.
14. Rimaroli C, Bruzzese T. Overview of SPA-S-843 in vitro activity against filamentous fungi. Chemother 2000; 46: 28-35.
15. Kantarcioglu AS, Yücel A. Species distribution and antifungal susceptibility pattern of yeasts and molds isolated at Cerrahpasa Medical Faculty Deapartment of Microbiology and Clinical Microbiology Deep Mycoses Laboratory between 01 April 1999-27 March 2001. Cer J Med 2002; 33: 7-19.